On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

As the prospect of sector-specific tariffs under the second Trump administration continues to rattle drugmakers, a more ...

As tariff threats and FDA staff cuts thrust the biopharma world into uncharted waters, President Donald Trump is offering the ...

An investigation into the national security implications of pharma imports has been underway for two weeks, the Trump ...

Employees of companies regulated by the FDA—such as pharmas or biotechs—are no longer allowed to serve as members of FDA ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in ...

After exploring a rival buyout offer worth 50% more than its first, bluebird bio is back where it started. | After striking ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

After a batch of much-anticipated reciprocal tariffs spared pharmaceuticals in early April, drugmakers, medtech companie | ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

One of the FDA’s recently departed top officials is weighing in on the wide-ranging staff cuts at the agency and how they ...

Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of.  | The combined company is ...